Related Experiment Video

Updated: Jun 3, 2026

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

Ranolazine as a therapeutic agent for diabetic cardiomyopathy: reducing endoplasmic reticulum stress and inflammation

Matin Mohyadini1, Aghele Fahimi1, S Zahra Bathaie1,2

  • 1Department of Clinical Biochemistry, Faculty of Medical Sciences, Tarbiat Modares University (TMU), P.O. Box: 14155-331, Ale-ahmad Ave., Tehran, Iran.

BMC Pharmacology & Toxicology
|May 28, 2025
PubMed
Abstract

Insights

Ranolazine treatment improved diabetic cardiomyopathy in rats by reducing oxidative stress, endoplasmic reticulum stress, and inflammation. This suggests ranolazine may be a potential therapy for diabetic heart disease.

Area of Science:

  • Cardiovascular Research
  • Diabetology
  • Pharmacology

Background:

  • Diabetic cardiomyopathy (DCM) is a heart complication of diabetes.
  • Oxidative stress, ER stress, and inflammation drive DCM.
  • Ranolazine shows potential cardioprotective effects.

Purpose of the Study:

  • Investigate ranolazine's effects on oxidative stress, ER stress, and inflammation in type 2 diabetic rat hearts.
  • Assess ranolazine's therapeutic potential for DCM.

Main Methods:

  • Type 2 diabetes induced in Wistar rats using Nicotinamide and Streptozotocin.
  • Ranolazine administered orally for eight weeks.
  • Evaluated body weight, heart weight, serum glucose, troponin-I, oxidative stress, ER stress, and inflammatory markers.

Main Results:

  • Ranolazine improved body weight and reduced heart weight in diabetic rats.
  • Treatment lowered serum troponin-I, oxidative stress (MDA), ER stress (GRP78, XBP1), and inflammation (IL1β).
  • Ranolazine increased antioxidant enzymes (SOD, GSH).

Conclusions:

  • Ranolazine demonstrates protective effects against diabetic cardiomyopathy.
  • The drug attenuates key pathological pathways: oxidative stress, ER stress, and inflammation.
  • Further research is warranted to explore ranolazine as a DCM therapeutic.
Keywords:
CardiomyopathyDiabetesER stressInflammationRanolazine

More Related Videos

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes11:00

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes

Published on: September 18, 2017

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury07:23

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury

Published on: March 7, 2022

Related Concept Videos

Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...